GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Generation Bio Co.
Generation Bio is a biotech company developing a novel gene therapy platform. Its stock price represents a venture bet on its scientific developments. The stock price reflects high volatility and reliance on preclinical and clinical trial data.
Share prices of companies in the market segment - Dna
Generation Bio is a biotech company developing non-viral gene therapy that promises to be safer and more scalable. We've categorized it as "DNA." The chart below shows how investors value companies working on the next generation of gene therapy.
Broad Market Index - GURU.Markets
Generation Bio is a biotech company developing non-viral gene therapy that promises to be safer and more scalable. Part of the GURU.Markets index, it's working on the next generation of gene therapy. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
GBIO - Daily change in the company's share price Generation Bio Co.
Generation Bio Co.'s daily share price fluctuations reflect the extreme volatility inherent in gene therapy companies. This metric is a measure of sensitivity to preclinical and clinical trial data.
Daily change in the price of a set of shares in a market segment - Dna
Generation Bio Co. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with GBIO, which focuses on gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Generation Bio is a biotech company working on gene therapy that doesn't require viruses. This is a potentially revolutionary approach. The company's stock reflects the high hopes and risks associated with breakthrough technologies and influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Generation Bio Co.
Generation Bio's year-over-year performance is a story of developing a new approach to gene therapy without the use of viruses. Its 12-month market cap depends entirely on progress in preclinical research. Its valuation reflects investors' faith in its technology's ability to overcome the limitations of existing gene delivery methods.
Annual dynamics of market capitalization of the market segment - Dna
Generation Bio Co. is a biotech company developing a new approach to gene therapy that doesn't require the use of viruses. Its stock price is entirely dependent on the results of preclinical and clinical trials. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Generation Bio is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Generation Bio Co.
Generation Bio is a biotech company developing gene therapy. Being an early-stage company, its monthly valuation is based on the potential of its scientific platform. News about preclinical studies and technological breakthroughs are the main drivers of its value.
Monthly dynamics of market capitalization of the market segment - Dna
Generation Bio is developing a new type of gene therapy that doesn't integrate into the patient's genome, which may be safer. This is at the cutting edge of biotechnology. The chart below shows how much investors believed in breakthrough, yet unproven, approaches to gene therapy, and how their expectations changed over the course of the year.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Generation Bio is a biotech company developing a new method for delivering gene therapy without the use of viruses. This is a fundamentally scientific story. Its stock price reflects the progress of research on this complex platform and is unaffected by market cycles, betting on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Generation Bio Co.
Generation Bio is a biotech company working in the cutting-edge field of gene therapy. Its weekly stock price is highly volatile, driven by news of progress in its research, particularly in non-viral gene delivery, a "holy grail" for the industry.
Weekly dynamics of market capitalization of the market segment - Dna
Generation Bio is a biotech company working in the cutting-edge field of gene therapy. Its weekly stock price is highly volatile, driven by news of progress in its research, particularly in non-viral gene delivery, a "holy grail" for the industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Generation Bio, a biotech company, live in a world of their own. Their performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the market.
Market capitalization of the company, segment and market as a whole
GBIO - Market capitalization of the company Generation Bio Co.
Generation Bio's market capitalization tells the story of the development of a new approach to gene therapy that doesn't rely on viral vectors. This biotech's stock price reflects investor expectations for its innovative platform. Its volatility reflects the market's reaction to preclinical data that could confirm or refute this bold scientific approach.
GBIO - Share of the company's market capitalization Generation Bio Co. within the market segment - Dna
Generation Bio is a biotech company developing a novel non-viral gene therapy platform. Its market capitalization reflects the breakthrough potential of its technology. The chart below shows the high valuation volatility typical of preclinical companies with ambitious goals.
Market capitalization of the market segment - Dna
Generation Bio is developing a gene therapy platform that does not require viral vectors, potentially making treatment safer and more universal. The chart below shows the overall market capitalization of the DNA technology sector. It reflects the scientific search for the "holy grail" of gene therapy—safe and effective gene delivery.
Market capitalization of all companies included in a broad market index - GURU.Markets
This shows gene therapy without viruses. Generation Bio is developing a new method for delivering genetic material into cells that may be safer than traditional viral vectors. Its volatile line on the chart is a bet on this fundamental scientific breakthrough, which could change the entire industry.
Book value capitalization of the company, segment and market as a whole
GBIO - Book value capitalization of the company Generation Bio Co.
Generation Bio's book value is derived from its scientific platform for developing non-viral gene therapy capable of delivering large genetic "packets," and its financial reserves. This represents breakthrough scientific capital. The chart shows how the company accumulates and expends enormous resources to solve one of the most complex problems in gene therapy.
GBIO - Share of the company's book capitalization Generation Bio Co. within the market segment - Dna
Generation Bio is a company developing gene therapy that does not integrate into the patient's genome. Its assets are cutting-edge laboratories. The chart shows a minimal share in physical assets, as its value lies in its unique scientific platform.
Market segment balance sheet capitalization - Dna
Gene therapy development, as the BCap_Ges chart for biotech shows, is a knowledge-intensive process. Generation Bio operates in this environment, investing its capital in creating a unique non-viral delivery platform rather than building traditional factories.
Book value of all companies included in the broad market index - GURU.Markets
Generation Bio's assets include cutting-edge laboratories and capital for the development of non-viral gene therapies. Its book value provides the financial foundation for the creation of a new technological platform that could lead to the development of safer and more versatile tangible gene therapies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Generation Bio Co.
Generation Bio is working on a new gene therapy technology that doesn't use viruses. This is fundamental science. A company's book value represents cash in its accounts. Its market capitalization represents its bet on a scientific breakthrough. The MvsBCap chart will reflect the market's assessment of the likelihood that its cutting-edge, yet risky, technology will work.
Market to book capitalization ratio in a market segment - Dna
Generation Bio is a biotech company working on non-viral gene therapy. Its valuation is entirely dependent on the success of its breakthrough scientific platform. The chart reflects investors' high expectations for the future of this new approach to medicine.
Market to book capitalization ratio for the market as a whole
Generation Bio is developing a new class of gene therapy that does not require viral delivery. This could make the therapy safer and more universal. The company's market value is a bet on the success of this breakthrough scientific platform. The chart reflects the high expectations for next-generation gene therapy.
Debts of the company, segment and market as a whole
GBIO - Company debts Generation Bio Co.
Generation Bio, a biotech company developing a new type of gene therapy, is investing all its capital in preclinical research and platform development. Creating breakthrough technology requires massive investments long before any revenue is generated. This chart shows the company's financial trajectory at the forefront of genetic medicine.
Market segment debts - Dna
Generation Bio is a biotech company developing a new gene therapy platform that doesn't rely on viral vectors. Developing such a breakthrough and complex technology requires massive long-term investments. This chart shows how the company funds its ambitious research at the earliest stages of development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Generation Bio Co.
Generation Bio aims to develop a new class of DNA-based gene therapy. This chart reflects the company's enormous financial needs to conduct revolutionary, but extremely expensive, research. The high level of debt underscores the company's betting on a scientific breakthrough that will either lead to massive success or failure.
Market segment debt to market segment book capitalization - Dna
Generation Bio is a biotech company developing non-viral gene therapy for rare diseases. This chart illustrates the debt burden in the cutting-edge gene therapy sector. It provides insight into how the company's financial strategy for funding its innovative platform is typical for this high-risk field.
Debt to book value of all companies in the market
Generation Bio is a biotechnology company developing a new class of gene therapy without the use of viruses. The overall debt burden, visible in the chart, shapes the investment landscape for science-intensive industries. Access to long-term capital necessary for breakthrough research in DNA therapy is highly dependent on market stability.
P/E of the company, segment and market as a whole
P/E - Generation Bio Co.
For Generation Bio, a gene therapy company, this chart reflects the high but risky expectations of investors. Its valuation is based not on profits, but on the potential of its technology to treat rare genetic diseases, where the success of a single drug could lead to a multibillion-dollar business.
P/E of the market segment - Dna
This chart shows the average price-to-earnings ratio for the gene therapy sector, where Generation Bio operates. The industry's valuation is based on future potential. The chart illustrates the general level of expectations and provides context for understanding how revolutionary the market considers Generation Bio's technology, even compared to other biotech companies.
P/E of the market as a whole
Generation Bio is a biotech company developing a new approach to gene therapy that doesn't require viruses to deliver genetic material. This should make the treatment safer and more universal. This chart shows risk appetite in biotech. It helps understand whether the market believes in the breakthrough potential of this non-viral platform and its perceived chances of success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Generation Bio Co.
Generation Bio is a biotech company developing a new approach to gene therapy that doesn't require viruses to deliver genes. This could make the therapy safer. This chart shows analysts' confidence in the potential for this innovative scientific platform to reach successful clinical trials.
%20P%2FE%20Generation%20Bio%20Co.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Generation-Bio-Co.&v=1772555089436 "Chart of the company's future (projected) P/E Generation Bio Co.")
Future (projected) P/E of the market segment - Dna
Generation Bio is a biotech company developing a new form of gene therapy that doesn't require integration into the patient's genome, potentially making it safer. This chart shows its expected future profitability, allowing one to assess how highly the market values this breakthrough scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772555089466 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Generation Bio is a biotech company developing a new class of gene therapy. This is fundamental science with enormous potential, but also high risks. This chart, reflecting the market's risk appetite, is vital for the company. Investor optimism allows it to fund such breakthrough, yet long-term, scientific research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772555089505 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Generation Bio Co.
Generation Bio Co. is developing a new class of gene therapy without the use of viruses, which could make it safer and more universal. The company's finances represent significant investments in science. This chart shows the capital burn on the path to creating a platform capable of treating rare and common genetic diseases.
Profit of companies in the market segment - Dna
Generation Bio is a biotech company developing a new platform for virus-free gene therapy, which could make treatment safer and more universal. This graph reflects the high potential and risks in the gene therapy sector, where the development of a non-viral delivery system could be a true revolution and open up a huge market.
Overall market profit
Generation Bio is developing a new type of gene therapy. This is one of the most advanced and capital-intensive areas of science. The overall economic backdrop shown by this chart is critically important, as it determines the flow of venture capital and the willingness of major pharmaceutical companies to invest in revolutionary platforms.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Generation Bio Co.
Generation Bio is developing a new class of gene therapy without the use of viruses, which could make treatment safer and more universal. This is a potentially revolutionary approach. This chart represents the collective opinion of analysts on the likelihood of a scientific breakthrough and the long-term commercial potential of this platform.
%20profit%20of%20the%20company%20Generation%20Bio%20Co.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Generation-Bio-Co.&v=1772555089568 "Graph of future (projected) profit of the company Generation Bio Co.")
Future (predicted) profit of companies in the market segment - Dna
Generation Bio is a biotech company developing a new class of gene therapy that doesn't require viruses to deliver genetic material. Its platform aims to create long-acting, overdose-free treatments. This chart shows profitability forecasts for the biotech sector, reflecting hopes for safer and more universal approaches to gene therapy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772555089579 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Generation Bio Co. is developing gene therapy for rare diseases. This is a cutting-edge, but highly capital-intensive, area of medicine. The total profit forecast shown in the chart influences the overall investment climate and the market's willingness to fund long-term scientific research that may only bear fruit many years from now.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772555089681 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Generation Bio Co.
Generation Bio is developing a new class of gene therapy. This chart embodies the belief in a scientific breakthrough. The company's market capitalization, without revenue, demonstrates how highly investors value the potential of its platform for treating previously untreatable genetic diseases.
P/S market segment - Dna
Generation Bio Co. is developing a new class of virus-free gene therapy for rare and common diseases. This chart reflects the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are placing on the potential of the company's breakthrough platform, which could make gene therapy safer.
P/S of the market as a whole
Generation Bio is developing a new class of gene therapy based on closed-loop DNA, which does not integrate into the genome, potentially making treatment safer and more durable. This is the cutting edge of genetic medicine. This chart, showing the valuation of companies by actual revenue, highlights the enormous expectations for these technologies, which have the potential to revolutionize approaches to treating hereditary diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Generation Bio Co.
Generation Bio is a biotechnology company developing a new approach to virus-free gene therapy, which could make treatment safer and more universal. This chart reflects investor expectations for this breakthrough technology. The valuation depends entirely on the success of its preclinical and future clinical trials.
%20P%2FS%20Generation%20Bio%20Co.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Generation-Bio-Co.&v=1772555089791 "The graph of the company's future (projected) P/S Generation Bio Co.")
Future (projected) P/S of the market segment - Dna
Generation Bio is a biotech company developing a new class of virus-free gene therapy, which could make treatment safer and more accessible. This is a breakthrough, but unproven, technology. This chart shows how the market values its innovative platform compared to the gene therapy sector.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772555089796 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Generation Bio is a biotech company developing a new form of gene therapy that does not integrate into the patient's genome. This schedule, reflecting investor willingness to fund breakthrough scientific ideas, is critical for the company. Market optimism is essential for attracting massive funding for the development of this complex and potentially revolutionary technology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772555089803 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Generation Bio Co.
Generation Bio is a biotech company developing a new form of gene therapy (non-viral) with the potential to treat rare and common diseases. This chart shows revenue from collaborations with other companies. It illustrates the financial support for an ambitious scientific platform aimed at making gene therapy safer and more accessible.
Sales of companies in the market segment - Dna
Generation Bio Co. is a biotechnology company developing a new category of genetic drugs based on non-viral gene therapy. Its goal is to create durable and titratable treatments for rare and common diseases. The business is segmented into liver and retina programs. This chart reflects the financial flows associated with one of these areas.
Overall market sales
Generation Bio Co. is a biotechnology company developing a new gene therapy platform that does not use viruses to deliver genetic material. This approach could make gene therapy safer and more applicable to a wider range of diseases. The company's success depends on a breakthrough in this complex scientific field and could transform medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Generation Bio Co.
Generation Bio is a biotech company developing a new platform for viral-free gene therapy (ceDNA), which it believes will enable treatment of a broader range of diseases. Its projected future sales represent a long-term bet that its innovative approach will be successful and overcome the limitations of existing gene therapy methods.
%20sales%20of%20the%20company%20Generation%20Bio%20Co.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Generation-Bio-Co.&v=1772555089845 "Schedule of future (projected) sales of the company Generation Bio Co.")
Future (projected) sales of companies in the market segment - Dna
Generation Bio Co. is developing a new class of gene therapy that doesn't use viral vectors for the treatment of rare diseases. This graph reflects expectations for the gene therapy sector. It helps assess the scientific progress and investment analysts are predicting in developing safer and more effective gene delivery methods.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772555089848 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Generation Bio, a gene therapy company, is working to develop a new class of drugs. Its funding depends on investors' confidence in the breakthrough potential of its technology. This chart of overall sales forecasts reflects the market's overall risk appetite, which is critical to supporting such ambitious scientific projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772555089991 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Generation Bio Co.
Generation Bio Co. is a biotechnology company developing a new class of virus-free gene therapy for the treatment of rare and common diseases. This chart reflects its financial performance at the R&D stage, where significant investments in breakthrough scientific platforms are the foundation for future therapeutic solutions.
Market segment marginality - Dna
Generation Bio is a biotech company developing a new approach to gene therapy that doesn't require viruses to deliver DNA. The effectiveness of their platform could radically change the production and cost of gene therapy. The graph shows their operating costs as they work toward this ambitious goal.
Market marginality as a whole
Generation Bio Co. is a biotech company developing a new approach to gene therapy that doesn't require viruses to deliver genetic material. This could make gene therapy safer and more versatile. This chart shows the profitability of mature businesses, while GBIO's value is determined by the potential of its breakthrough scientific platform.
Employees in the company, segment and market as a whole
Number of employees in the company Generation Bio Co.
Generation Bio is working to develop a new type of gene therapy without the use of viruses. This graph shows the team of scientists tackling one of the most complex challenges in biotechnology. The size of this team reflects the enormous investment required to develop and validate this breakthrough and potentially safer technology.
Share of the company's employees Generation Bio Co. within the market segment - Dna
Generation Bio is developing a new approach to gene therapy that doesn't use viral vectors. This is a potentially safer method. Developing such a breakthrough platform requires a team of leading scientists. This chart illustrates the scale of its workforce in one of the most advanced fields of biotechnology.
Number of employees in the market segment - Dna
Generation Bio is a biotechnology company developing a new approach to gene therapy without the use of viruses. This chart reflects employment in the DNA technology sector. The explosive growth of geneticists and bioengineers is evidence of the revolution in gene medicine and the search for safer and more scalable gene delivery platforms, which is the mission of Generation Bio.
Number of employees in the market as a whole
Generation Bio is a company working on non-viral gene therapy. This is at the cutting edge of science, and its development depends on technological breakthroughs. This graph reflects the current labor market, but Generation Bio is hiring exceptional specialists to create technologies that will transform medicine and the economy of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Generation Bio Co. (GBIO)
Generation Bio Co. is a biotech company working on non-viral gene therapy. This chart demonstrates its enormous market capitalization per employee. The market values the platform's revolutionary potential to transform medicine, not its assets. The company's value lies in the intellect of its small team of scientists.
%20of%20the%20company%20Generation%20Bio%20Co.%20(GBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Generation-Bio-Co.-GBIO&v=1772555090089 "Chart of market capitalization per employee (in thousands of dollars) of the company Generation Bio Co. (GBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Generation Bio Co. is developing a new class of gene therapy that doesn't use viral vectors for the treatment of rare diseases. In the cutting-edge field of genetic engineering, this metric reflects how highly the market values their breakthrough scientific platform. It's an indicator of investor confidence in the potential of their technology and the value of their scientific team.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772555090103 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Generation Bio Co. is a biotech company developing a new approach to gene therapy that doesn't require viruses to deliver therapeutic genes. This could make gene therapy safer and more versatile. The chart illustrates the enormous potential the market sees in this breakthrough scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772555090130 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Generation Bio Co. (GBIO)
Generation Bio is a biotech company working on developing a new class of gene therapy (non-viral) that could be safer and reusable. This is extremely early and complex science. This graph (negative) shows how much capital the company is "burning" per scientist in an attempt to achieve a breakthrough in gene therapy, which will require massive investments before any profit can be realized.
%20Chart%20Generation%20Bio%20Co.%20(GBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Generation-Bio-Co.-GBIO&v=1772555090143 "Company Profit Per Employee (in thousands of dollars) Chart Generation Bio Co. (GBIO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Generation Bio is a biotechnology company developing a new class of gene therapy that doesn't rely on viruses. Their success depends on the breakthroughs their scientific team can achieve. This metric reflects the potential value created by each employee and serves as a benchmark for comparison with other companies in the field of genetic engineering.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772555090162 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Generation Bio (GBIO) is a biotech company working on non-viral gene therapy. This is one of the most advanced and complex R&D sectors. Its negative earnings per employee reflects the enormous investment in its research team, which is attempting to create a fundamentally new gene delivery platform without any products yet.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772555090164 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Generation Bio Co. (GBIO)
Generation Bio is a biotech company developing a new type of gene therapy without the use of viruses. Currently in the preclinical stage, it has no sales revenue. This graph will eventually show whether its revolutionary scientific platform can lead to commercial products.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Generation-Bio-Co.-GBIO&v=1772555090174 "Sales chart per company employee Generation Bio Co. (GBIO)")
Sales per employee in the market segment - Dna
Generation Bio is a biotech company working on non-viral gene therapy. They strive to create safer and more durable treatments for genetic diseases. This chart compares their revenue per employee (R&D) to the industry average. It reflects how productive their innovative scientific platform is in achieving their goals.
Sales per employee for the market as a whole
Generation Bio (GBIO) is a biotech company developing a new gene therapy platform (non-viral DNA delivery). This is an early-stage fundamental science company. The company has no commercial revenue and cannot have any. All employees are scientists. This chart will show $0, reflecting their long-term focus on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Generation Bio Co. (GBIO)
Generation Bio (GBIO) is developing a new type of gene therapy (non-viral) that promises to be safer and more durable. This fundamental science is in the very early, pre-clinical stage. This chart shows the number of investors who believe this technology is too far from reality and its risks are prohibitive.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Generation-Bio-Co.-GBIO&v=1772555090186 "Short Shares Chart for the Company Generation Bio Co. (GBIO)")
Shares shorted by market segment - Dna
Generation Bio is a biotech company working on "non-viral" gene therapy. They are attempting to deliver DNA into cells without the use of viruses, which should be safer. This chart shows the odds against the gene therapy sector, reflecting the extreme skepticism of investors regarding this highly complex and yet unproven technology.
Shares shorted by the overall market
Generation Bio (GBIO) is a biotech company focused on gene therapy. It's one of the most advanced and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off "research projects" without profits, like GBIO, en masse to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Generation Bio Co. (GBIO)
Generation Bio Co. is developing a "non-viral" gene therapy that could address the safety concerns of existing treatments. This is a breakthrough, but very early technology. This indicator tracks when investors are "overhyping" (above 70) the stock due to faith in the technology or "overselling" (below 30) due to slow progress.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Generation-Bio-Co.-GBIO&v=1772555090200 "RSI 14 indicator chart for the company's stock Generation Bio Co. (GBIO)")
RSI 14 Market Segment - Dna
Generation Bio is a biotech company developing a new form of gene therapy (ceDNA) that doesn't integrate into the genome, potentially making it safer and more repeatable. This chart measures the collective excitement in the gene therapy sector. It helps us understand whether the entire speculative segment is oversold.
RSI 14 for the overall market
For Generation Bio, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GBIO (Generation Bio Co.)
Generation Bio is a biotech company developing "non-viral" gene therapy (ceDNA), which does not integrate into the genome. This chart shows the average target price. Analysts' forecasts are based on preclinical data and the long-term potential of this innovative gene delivery platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GBIO-Generation-Bio-Co.&v=1772555090261 "A chart showing analyst consensus forecasts for the expected stock price. GBIO (Generation Bio Co.)")
The difference between the consensus estimate and the actual stock price GBIO (Generation Bio Co.)
Generation Bio is a biotech company working on a non-viral gene therapy platform (ceDNA), which is expected to be safer. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this complex but potentially breakthrough science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GBIO-Generation-Bio-Co.&v=1772555090284 "A chart showing the difference between the consensus forecast and the actual stock price. GBIO (Generation Bio Co.)")
Analyst consensus forecast for stock prices by market segment - Dna
Generation Bio is a biotech company developing a new "non-viral" gene therapy platform (ceDNA), which they believe is safer than traditional viral vectors (AAV). This chart shows general expectations for the DNA technology sector. It reflects whether experts believe in a breakthrough in "non-viral" gene delivery.
Analysts' consensus forecast for the overall market share price
Generation Bio is a biotech company working on "non-viral" gene therapy. Their goal is to deliver genetic drugs (DNA) via lipid nanoparticles, which is safer than viruses. This chart shows the overall "risk appetite" in the market. For GBIO, working in one of the most advanced and risky areas of medicine, overall market optimism is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Generation Bio Co.
Generation Bio is a non-viral gene therapy company. Their signature approach is delivering large genes (ceDNA) without the use of viruses (AAV), which should make the therapy safer and more repeatable. This graph is a clear indicator of their faith in their deep science. It reflects their (very long) R&D journey and their risky bet that their non-viral approach will work.
AKIMA Market Segment Index - Dna
Generation Bio (GBIO) is a biotech company developing a new form of gene therapy (non-viral, closed DNA - ceDNA). Their goal is to create safer and more durable gene therapies. The chart shows the average index for the segment, helping investors assess how this cutting-edge, yet very early, technology compares to the average risk in the gene engineering sector.
The AKIM Index for the overall market
Generation Bio is a biotech company developing non-viral gene therapy (ceDNA) for the treatment of rare and common diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop critical for evaluating this ambitious platform solving gene delivery problems.
